TROG 98.04 - Liver Metastases - TROG Cancer Research

By w.paterson
15 August, 2021
0 Comments

Phase II Study Examining the Efficacy of Short Fractionation Radiotherapy for the Palliation of Liver Metastases

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

TOPGEAR trial results published in the New England Journal of Medicine

18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was

Join us to raise $35,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Phase II Study Examining the Efficacy of Short Fractionation Radiotherapy for the Palliation of Liver Metastases

TROG 98.05 – Solitary Brain Metastases

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000

TROG 98.04 – Liver Metastases

Phase II Study Examining the Efficacy of Short Fractionation Radiotherapy for the Palliation of Liver Metastases

TROG 98.05 – Solitary Brain Metastases

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Related Post

TOPGEAR trial findings published in NEJM

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

Join us to raise $35,000